Skip to main content
Top

06-10-2019 | Dulaglutide | ADA 2019 | Article

Expert commentary: The REWIND trial

share
SHARE
print
PRINT
insite
SEARCH

John Wilding discusses how the results of the REWIND study add to our knowledge of the effects of the glucagon-like peptide-1 receptor agonist class in people with varying degrees of cardiovascular risk (3:37).

share
SHARE
print
PRINT